Skip to main content
. 2020 Aug 14;10:13843. doi: 10.1038/s41598-020-70673-z

Figure 2.

Figure 2

Effect of immune checkpoint-blockade on recurrent ocular herpes infection and disease in HSV-1 infected HLA Tg rabbits. (a) Schematic representation of HSV-1 ocular infection, α-PD-1/α-LAG-3 mAbs treatment, immunological, virological, and disease analyses in HLA Tg rabbits ocularly infected with HSV-1. HLA-Tg rabbits from Group-1 were ocularly infected with HSV-1 and treated with α-PD-1/α-LAG-3 mAbs whereas HLA-Tg rabbits placed in Group-2 were also ocularly infected with HSV-1 but not treated with α-PD-1/α-LAG-3 mAbs. Based on the severity and frequency of recurrent ocular herpetic disease, the rabbits were scored between 0 and 4 and subsequently categorized into SYMP and ASYMP groups. (b) HSV-1 viral titers in the eyes of α-PD-1/α-LAG-3 treated and α-PD-1/α-LAG-3 untreated HLA Tg rabbits. Infectious virus particles were quantified from eye swabs of α-PD-1/α-LAG-3 treated and α-PD-1/α-LAG-3 untreated HLA Tg rabbits. (c) Representative images showing recurrent ocular herpetic disease in HSV-1 infected SYMP HLA Tg rabbits. (d) Trigeminal ganglia were extracted from HSV-1 infected non-treated HLA Tg rabbits on day 15 post-infection. The effect of α-PD-1 or α-LAG-3 mAbs treatment on virus reactivation, ex vivo from TG explants, was assessed along with that of isotype mAb control.